Stock exchanges & markets

Overview Watchlists

FDA approves Novartis Rhapsido for symptomatic dermographism in adults

7. Oct 2026

(AWP Alliance News) - Novartis won FDA clearance for Rhapsido (remibrutinib) to treat adults with symptomatic dermographism inadequately controlled by H1 antihistamines, marking the first approved drug for the condition. The decision expands Rhapsido's US label beyond chronic spontaneous urticaria.

In the Phase III RemIND trial, 29.3% of patients on Rhapsido had complete hive resolution at Week 12 versus 14.0% on placebo.

https://www.globenewswire.com/NewsRoom/ReleaseNg/402522954

Disclaimer: This news brief was created using generative artificial intelligence. Novartis AG published the original content used to generate this news brief via GlobeNewswire on October 07, 2026, and is solely responsible for the information contained therein.

Learn more about our offers

  • Keep a close eye on your favourite shares

    Watchlist

    Don’t miss out on share price trends. Track your favourite shares (CH, EU & US) in real time with customised watchlists.

    Sign up now

  • Compare ETFs systematically

    ETF Compass

    Find the products that suit your investment goals.

    Try the ETF Compass

  • How to find the best shares

    theScreener

    Search through around 6,500 securities using criteria such as opportunities and risks or expected dividend yield.

    Test now